Olaparib CAS 763113-22-0 Watson International Limited
Olaparib - Wikipedia
Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies | Science Advances
Olaparib – Wikipedia
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. - Abstract - Europe PMC
BRCA Support Liverpool
![Solid phase radiosynthesis of an olaparib derivative using 4-[18F] fluorobenzoic acid and in vivo evaluation in breast and prostate cancer xenograft models for PARP-1 expression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0969805122020856-ga1.jpg "Solid phase radiosynthesis of an olaparib derivative using 4-[18F] fluorobenzoic acid and in vivo evaluation in breast and prostate cancer xenograft models for PARP-1 expression - ScienceDirect")
Solid phase radiosynthesis of an olaparib derivative using 4-[18F] fluorobenzoic acid and in vivo evaluation in breast and prostate cancer xenograft models for PARP-1 expression - ScienceDirect
Olaparib | C24H23FN4O3 | ChemSpider
令癌莎- Wikiwand
763113-22-0 Olaparib - Watson International Ltd
PharmaWiki - Olaparib
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
HemOnc.org | A Hematology Oncology Wiki
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
令癌莎- Wikiwand
olaparib | New Drug Approvals
Olaparib | C24H23FN4O3 | CID 23725625 - PubChem
Olaparib | AZD-2281 | CAS#763113-22-0 | MedKoo
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
PARP inhibitor - Wikipedia
A Wikipedia edit-a-thon for women in cancer research
